Patrick Aebischer

Vice-Chairman of the Board of Directors of Lonza Group Ltd (April 2014 until April 2020), Independent member of the Board of Directors of Lonza Group Ltd (March 2008 until April 2020)

Patrick Aebischer holds a doctorate in medicine from the University of Geneva (CH). He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences.

Current Activities and Functions

Public Company Boards:

  • Member of the Board of Directors of Logitech SA (since 2016)
  • Member of the Board of Directors of Nestlé SA (since 2015)

Further Appointments:

  • Chairman of the Board of Directors of Arctos SA (since 2019)
  • Senior Partner of NanoDimension Management Limited (since 2017)
  • Scientific technical committee member of the Italian Institute of Technology (since 2015)
  • Chairman of the Novartis Venture Fund (since 2014)
  • Member of the Singapore Biomedical Sciences International Advisory Council (since 2013)
  • Chairman of the Board of Amazentis SA (since 2007)
  • Professor of Neurosciences, Swiss Federal Institute of Technology Lausanne (EPFL) (since 2000)
Former Activities and Functions
  • Senate member of the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (2016–2019)
  • Representative of the EPFL on the boards of various Swiss foundations
  • President of the Swiss Federal Institute of Technology of Lausanne (EPFL) (2000–2016)
  • Member of the Foundation Board of the World Economic Forum (2013–2016)

Margot Scheltema

Independent member of the Board of Directors of Lonza Group Ltd (April 2012 until April 2020)

Margot Scheltema holds a doctorate in international law from the University of Amsterdam and a Master of International Affairs (MIA) from Columbia University in New York, NY (USA). Margot Scheltema has substantial knowledge as a finance, corporate governance and risk management expert, demonstrated by her operative roles in finance and management and supervisory roles in the financial sector (bank, central bank, insurance and pension funds).

Current Activities and Functions
  • NEDAP (NE Director) NV (since 2018)

Further Appointments:

  • Vice-chair of the Supervisory Board of the Dutch Central Bank (since 2015) (financial institution)
  • Member of the Central Plan Committee Dutch Planning Bureau (since 2014)
  • Chair of the Monitoring Committee of the Dutch Pension Fund Code (since 2014)
  • Council to the Enterprise Chamber of the Amsterdam Court of Appeal (since 2013)
  • Member of the Supervisory Board of Warmtebedrijf Rotterdam (since 2011)
  • Member of the Supervisory Board of TNT Express (since 2011)
Former Activities and Functions
  • Vice-Chair of the Supervisory Board of Triodos Bank (2006–2015)
  • Member of the Supervisory Board of ASR NV (2008–2015)
  • External Member of the Audit Committee of the Dutch pension fund ABP (2010 to July 2014) (financial institution)
  • Member of the Supervisory Board of the Rijksmuseum (2007–2015)
  • Member of the AFM External Reporting Committee (2006–2012)
  • Finance Director of Shell Nederland BV (2004–2008)
  • Various managerial positions in finance within the Shell Group (1985–2004)including Senior M&A Adviser for Shell Oil Products Latin America

Dr Moncef Slaoui

Independent member of the Board of Directors of Lonza Group Ltd (April 2020 until May 2020)

Dr Moncef Slaoui brings to Lonza extensive experience from his career with GlaxoSmithKline spanning nearly 30 years. In this time, he held a number of leadership positions, including Member of the Board of GSK PLC, Chairman of Pharmaceutical R&D; and Chairman of Global Vaccines. Currently, Dr Slaoui is partner at Medicxi, a venture capital firm specializing in seed, Series A, early stage and late stage life sciences investments; he also sits on various biotechnology companies’ boards. Dr Slaoui received his Ph.D. in Molecular Biology and Immunology from Brussels University in 1983. He later received an accelerated Master of Business Administration from IMD in Lausanne (Switzerland) in 1998.

Current activities and functions

Further Mandates:

  • Chairman of Monopteros (A Medicxi Company) (since 2018)
  • Chairman of Divide & Conquer (A Medicxi Company) (since 2017)
  • Chairman of Sutrovax (since 2017)
  • Chairman Galvani Bioelectronics (since 2016)
  • Chairman of Clasado (since 2017)

Activity:

  • Partner at Medicxi (since 2017)
Former activities and functions
  • Independent Member of the Board of Directors of Moderna (2017–2020)
  • Member of the Advisory Board of the Qatar Foundation (2009–2020)
  • Member of the Board of Directors of International AIDS Vaccines Initiatives (2015–2017)
  • Member of the Board of GSK PLC (2006–2017)
  • Chairman, Global Vaccines of GSK PLC (2009–2017)
  • Chairman, Global Research & Development of GSK PLC (2006–2015)
  • Various leadership roles in Research & Development including Worldwide Business Development & External Alliances (1988–2003)